We will have limited operations from 15:00 Wednesday 24 December 2025 (AEDT) until Friday 2 January 2026. Find out how to contact us during the holiday period.
ZERBAXA (Merck Sharp & Dohme (Australia) Pty Ltd)
Product name
ZERBAXA
Date registered
Evaluation commenced
Decision date
Approval time
169 working days (255)
Active ingredients
ceftolozane sulfate; tazobactam sodium
Registration type
EOI
Indication
ZERBAXA (powder for injection) is now also indicated for the treatment of nosocomial pneumonia, including ventilator-associated pneumonia (VAP) infections in adults suspected or proven to be caused by designated susceptible microorganisms.